Filter Releases
 
Press Releases
Date Title and Summary View
Apr 5, 2017
WALTHAM, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today announced that it will report First Quarter 2017 financial results on May 3, 2017, and that it will ...
Apr 3, 2017
The data was presented in an Oral Late-Breaker at Annual Endocrine Society Meeting "ENDO 2017" on April 1 Additional analysis of BMD gains at the wrist and fracture reductions at the ultradistal radius compared to placebo and teriparatide were presented on April 2 ...
Mar 31, 2017
Preclinical models of elacestrant activity in preclinical models of endocrine treatment resistancePreclinical studies of RAD140 activity and mechanism of action in breast cancer models WALTHAM, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical com...
Mar 10, 2017
WALTHAM, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that the U.S. Food and Drug Administra...
Feb 28, 2017
WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Cowen and ...
Feb 23, 2017
US FDA PDUFA for abaloparatide-SC is March 30, 2017 Build out of Commercial Organization to be completed in 1Q 2017 24-month ACTIVExtend trial has concluded, Radius to report top-line results in 2Q 2017 WALTHAM, Mass., Feb. ...
Feb 1, 2017
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the incidence of new vert...
Jan 31, 2017
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 4:30 p.m. ET on Thurs...
Jan 6, 2017
WALTHAM, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annua...
Dec 8, 2016
 -3 patients had confirmed partial responses by RECIST criteria from ongoing Phase I studies with RAD1901 in patients with advanced estrogen receptor positive breast cancer- -In the Phase 1 dose escalation and expansion study, 14 heavily pretreated patients remained on RAD1901 for equal t...
Nov 3, 2016
ACTIVE Phase 3 trial results published in Journal of American Medical Association and Journal of Bone Mineral ResearchRadius to present three abstracts on RAD1901 at San Antonio Breast Cancer Symposium in DecemberWALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Radi...
Nov 1, 2016
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the ...
Oct 12, 2016
WALTHAM, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2016 financial results on Thursday, November 3, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thur...
Sep 19, 2016
-Second Generation Transdermal Patch Achieves Pharmacokinetic Objectives— WALTHAM, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Radius Health Inc. (Nasdaq:RDUS) a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, onc...
Sep 18, 2016
WALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (...
= add release to Briefcase